Research Topics
Genomes and GenesSpecies | Andrew SiderowfSummaryAffiliation: University of Pennsylvania Country: USA Publications
| Collaborators
|
Detail Information
Publications
Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome StudyAndrew Siderowf
Parkinson s Disease and Movement Disorders Center, Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19107, USA
Mov Disord 27:406-12. 2012....
[99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson diseaseA Siderowf
Parkinson Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, USA
Neurology 64:1716-20. 2005..In vivo imaging of the dopamine transporter with [99mTc]TRODAT-1 (TRODAT) and olfactory testing have both been proposed as potential biomarkers in Parkinson disease (PD)...- Preclinical diagnosis of Parkinson's disease: are we there yet?Andrew Siderowf
Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, 330 South 9th Street, Philadelphia, PA 19107, USA
Curr Neurol Neurosci Rep 6:295-301. 2006..The current challenges are to refine these technologies and to determine how they should be employed so that their use is ethical, practical, and meaningful to at-risk individuals... - Premotor Parkinson's disease: clinical features, detection, and prospects for treatmentAndrew Siderowf
Parker Family Professor of Neurology Director, Parkinson s Disease and Movement Disorder Center, University of Pennsylvania, USA
Ann Neurol 64:S139-47. 2008..Ultimately, the value of screening for PD depends on development of neuroprotective treatments for PD that would create an imperative for early identification and treatment... - Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's diseaseAndrew Siderowf
Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Mov Disord 22:2249-55. 2007..Further research is warranted to determine whether a history of lower caffeine consumption confers additional risk for the development of PD in hyposmic relatives of PD patients... 
Genetic influences on cognitive decline in Parkinson's diseaseJames F Morley
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvalia, USA
Mov Disord 27:512-8. 2012..Clinically, these results suggest that genotyping can provide information about the risk of future cognitive decline for PD patients...- Plasma multianalyte profiling in mild cognitive impairment and Alzheimer diseaseWilliam T Hu
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
Neurology 79:897-905. 2012..Here we aim to determine plasma biomarkers associated with AD in 2 independent cohorts and validate the findings in the multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI)... - Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease studyRoy N Alcalay
Department of Neurology, Columbia University, New York, NY 10032, USA
Arch Neurol 67:1116-22. 2010..To assess the frequency and clinical characteristics of carriers of previously identified mutations in 6 genes associated with early-onset Parkinson disease (PD) and provide empirical data that can be used to inform genetic counseling... - Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's diseaseRoy N Alcalay
Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
J Clin Exp Neuropsychol 32:775-9. 2010..GBA carriers reported more impairment, but MMSE performance did not differ among genetic groups. Detailed neuropsychological testing is required to explore the association between cognitive impairment and GBA mutations... - Plasma epidermal growth factor levels predict cognitive decline in Parkinson diseaseAlice S Chen-Plotkin
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Ann Neurol 69:655-63. 2011..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD... - Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's diseaseDaniel Weintraub
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3339, USA
Brain 135:170-80. 2012..In addition, an Alzheimer's disease pattern of brain atrophy may be a preclinical biomarker of cognitive decline in Parkinson's disease... - Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's diseaseWilliam T Hu
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Acta Neuropathol 120:385-99. 2010.... - Everyday action impairment in Parkinson's disease dementiaTania Giovannetti
Department of Psychology, Temple University, Philadelphia, Pennsylvania 19122, USA
J Int Neuropsychol Soc 18:787-98. 2012..jins, 2012, 18, 1-12)... - Building an integrated neurodegenerative disease database at an academic health centerSharon X Xie
Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Alzheimers Dement 7:e84-93. 2011..These comparative studies rely on powerful database tools to quickly generate data sets that match diverse and complementary criteria set by them... - Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid
Department of Neurology, University of Rochester, Rochester, New York, USA
Mov Disord 25:1801-8. 2010..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted... - Association between cognition and function in patients with Parkinson disease with and without dementiaEmily Rosenthal
Department of Neurology, Division of Geriatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19107, USA
Mov Disord 25:1170-6. 2010..87 vs. 0.75, P = 0.0008). Cognition is associated with impairment in ADL function, even in nondemented patients with PD. However, sensitive cognitive assessment measures may be needed to identify these functionally relevant impairments... - Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control studyDaniel Weintraub
From the University of Pennsylvania School of Medicine D W, K P, A S and Parkinson s Disease and Mental Illness Research, Education and Clinical Centers D W, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
Neurology 80:176-80. 2013..To determine the frequency and correlates of impulse control and related behavior symptoms in patients with de novo, untreated Parkinson disease (PD) and healthy controls (HCs)... - Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's diseaseRandolph Stephenson
Department of Neurology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
Mov Disord 25:2099-104. 2010..These findings suggest that severity of olfactory impairment early in the disease course may be a useful marker for the risk of neuropsychiatric complications of PD... - Treatment disparities in Parkinson's diseaseNabila Dahodwala
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Ann Neurol 66:142-5. 2009..In a group with the same healthcare insurance, disparities in PD treatment exist. Physician and community awareness of these racial differences in PD treatment is the first step in addressing healthcare disparities... - Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairmentWilliam T Hu
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
Acta Neuropathol 119:669-78. 2010..In summary, our targeted proteomic screen revealed novel CSF biomarkers that can improve the distinction between AD and non-AD cases by established biomarkers alone... - Rasagiline improves quality of life in patients with early Parkinson's diseaseKevin M Biglan
Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
Mov Disord 21:616-23. 2006..Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline... - Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scoresEugenia Mamikonyan
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
Parkinsonism Relat Disord 15:226-31. 2009..We report on the frequency and characteristics of cognitive deficits in PD patients with intact global cognition based on Mini-Mental State Examination (MMSE) performance... - Delayed Parkinson's disease diagnosis among African-Americans: the role of reporting of disabilityNabila Dahodwala
Parkinson s Disease Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, PA, USA
Neuroepidemiology 36:150-4. 2011..We sought to compare the stage at which African-American and white PD patients present for healthcare, and determine whether perception of disability accounts for racial differences... - Impact of belief in neuroprotection on therapeutic intervention in Parkinson's diseaseRodger J Elble
Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
Mov Disord 25:1082-6. 2010..We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment... - Parkinson's at risk syndrome: can Parkinson's disease be predicted?Matthew B Stern
Penn Comprehensive Neuroscience Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Mov Disord 25:S89-93. 2010..Further, our concept of PD risk will change the nosology of PD as those now considered "at-risk" may ultimately be considered to already have the disease... - Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating ScaleDaniel Weintraub
Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104 2676, USA
Mov Disord 27:242-7. 2012..Preliminary results suggest that it can be used to support a diagnosis of these disorders, as well as to monitor changes in symptom severity over time... - F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired Parkinson disease patientsJames Connolly
Department of Neurology, Parkinson s Disease and Movement Disorders Center, Pennsylvania Hospital, Philadelphia, PA 19107, USA
Cogn Behav Neurol 21:83-6. 2008..To determine the utility of 8,12-isoprostaneF2alpha-VI (iP), a specific and sensitive index of lipid peroxidation, as a biomarker for dementia in Parkinson disease (PD)... - Can a screening questionnaire accurately identify mild Parkinsonian signs?Nabila Dahodwala
Parkinson s Disease and Movement Disorders Center, Pennsylvania Hospital, 330 South Ninth Street, Philadelphia, PA 19107, USA
Neuroepidemiology 39:171-5. 2012..Our objective was to assess the ability of a 9-item Parkinson's Disease Screening Questionnaire (PDSQ), which has high sensitivity in the detection of overt Parkinson's disease (PD), to detect MPS... - Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's diseaseAndrew Siderowf
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19107, USA
Mov Disord 21:746-53. 2006..01). In this selected group of patients, many of the short-term gains in HRQL persist beyond 18 months after STN implantation. Benefits in nonmotor aspects of HRQL such as bodily discomfort and stigma appear to be among the most durable... - Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathologyLeo F McCluskey
Department of Neurology, University of Pennsylvania School of Medicine, 330 S 9th St, Philadelphia, PA 19107, USA
Arch Neurol 66:121-4. 2009.... - Design of comprehensive Alzheimer's disease centers to address unmet national needsJohn Q Trojanowski
Institute on Aging, Philadelphia, PA, USA
Alzheimers Dement 6:150-5. 2010..The intent of this position paper is to stimulate thinking and foster the development of other or alternative models for a systematic approach to the study of dementia and movement disorders... - Premotor Parkinson's disease: concepts and definitionsAndrew Siderowf
Parkinson s Disease and Mov Disord Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Mov Disord 27:608-16. 2012.... - Screening questionnaires for parkinsonism: a systematic reviewNabila Dahodwala
Department of Neurology, University of Pennsylvania, PA, USA
Parkinsonism Relat Disord 18:216-24. 2012..However, the performance of these questionnaires varied based on the individual items, study sample, and method of administration. The performance of screening questionnaires in the detection of early or mild parkinsonism was modest... - A longitudinal program for biomarker development in Parkinson's disease: a feasibility studyBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Mov Disord 24:2081-90. 2009..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data... - Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's diseaseRandel L Swanson
Division of Nuclear Medicine, 110 Donner Building, H.U.P, 3400 Spruce Street, Philadelphia, PA, 19104, USA
Eur J Nucl Med Mol Imaging 32:302-7. 2005..This may reflect different pathophysiological processes of the two neurodegenerative diseases... - Clinical trials with rasagiline: evidence for short-term and long-term effectsAndrew Siderowf
Parkinson s Disease and Movement Disorders Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Neurology 66:S80-8. 2006.... - Preference-based quality-of-life in patients with Parkinson's diseaseAndrew Siderowf
Departments of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
Neurology 59:103-8. 2002..Because of this property, they are the appropriate measures of quality of life for cost-effectiveness analysis. Although preference-based scales are widely used, their validity has rarely been tested in specific patient groups... - Breaking the news: a survey of ALS patients and their caregiversLeo McCluskey
Department of Neurology, University of Pennsylvania, PA 19107, USA
Amyotroph Lateral Scler Other Motor Neuron Disord 5:131-5. 2004..Greater adherence to certain attributes of effective communication of bad news may improve the way physicians perform this difficult task... - Parkinson's disease: clinical features, epidemiology and geneticsA Siderowf
Parkinson s Disease and Movement Disorders Center, University of Pennsylvania, Philadelphia, Pennsylvania 19107, USA
Neurol Clin 19:565-78, vi. 2001..This article reviews the clinical features, epidemiology and genetics of PD, with emphasis on insights from recent genetic and epidemiological studies... - Emergence of complex, involuntary movements after gamma knife radiosurgery for essential tremorA Siderowf
Department of Neurology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA
Mov Disord 16:965-7. 2001..This case illustrates the need for long-term follow-up to fully evaluate the potential for complications following radiosurgery... - Racial differences in the diagnosis of Parkinson's diseaseNabila Dahodwala
Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Mov Disord 24:1200-5. 2009..Better understanding of the complex biological and social determinants of these disparities is critical to improve PD care... - Local institutional review board (IRB) review of a multicenter trial: local costs without local contextBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Ann Neurol 67:258-60. 2010..This may be an opportune time for the National Institute of Neurological Disorders and Stroke (NINDS) to adopt a central review model... - The organization of narrative discourse in Lewy body spectrum disorderSharon Ash
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
Brain Lang 119:30-41. 2011..These findings are consistent with a model of narrative discourse that includes executive as well as language components and with an impairment of the organizational component of narrative discourse in patients with PDD and DLB... - Co-morbidity of TDP-43 proteinopathy in Lewy body related diseasesHanae Nakashima Yasuda
Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, HUP Maloney 3rd Floor, Philadelphia, PA 19104 4283, USA
Acta Neuropathol 114:221-9. 2007..This study expands the concept of TDP-43 proteinopathies by implicating TDP-43 lesions in mechanisms of neurodegeneration in LB disorders... - Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of diseaseRachel Goldmann Gross
Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania Health System, Philadelphia, PA, USA
Neurosignals 16:24-34. 2008..These observations suggest that common targets for diagnosis and treatment of these disorders can be identified... - Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's diseaseK L Chou
Parkinson s Disease and Movement Disorders Center, University of Pennsylvania School of Medicine, Pennsylvania Hospital, 330 South Ninth Street, Philadelphia, PA 19107, USA
Parkinsonism Relat Disord 10:375-9. 2004..79, specificity 0.92). These findings show that TRODAT imaging can accurately differentiate early PD patients from controls and has the potential to improve the diagnosis of patients with early signs of PD... - Update on Parkinson diseaseAndrew Siderowf
Parkinson s Disease and Movement Disorders Center, University of Pennsylvania, 330 South 9th Street, Philadelphia, Pennsylvania 19107, USA
Ann Intern Med 138:651-8. 2003.... - Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interestDana Clay Falcone
Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA 19104, USA
J Genet Couns 20:384-95. 2011..Genetic education and counseling tools to address these needs were developed to provide patients with the ability to make informed and knowledgeable genetic testing decisions... - Premotor Parkinson's disease: clinical features and detection strategiesRandolph Stephenson
Parkinson s Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennysylvania 19107, USA
Mov Disord 24:S665-70. 2009..Current research to evaluate efficient screening methods and to understand the clinical and physiological features of "premotor" PD will lay the foundation for the screening and prevention strategies of the future... - CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson diseaseA Siderowf
Department of Neurology, 330 South 9th Street, Second Floor, Philadelphia, PA 19107, USA
Neurology 75:1055-61. 2010..Cognitive decline associated with Parkinson disease (PD) is common and highly disabling. Biomarkers that help identify patients at risk for cognitive decline would be useful additions to the clinical management of the disease... - Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15)Daniel Weintraub
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
Int J Geriatr Psychiatry 22:1025-30. 2007..Depression occurs frequently in patients with both Alzheimer's disease (AD) and Parkinson's disease (PD), but there has been little comparison of depression symptoms in the two populations... - Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trialAndrew Siderowf
Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Mov Disord 17:758-63. 2002..The findings are in agreement with previous reports on interrater reliability... - Piloting the NPF data-driven quality improvement initiativeMichael S Okun
National Parkinson Foundation Center of Excellence, University of Florida, Movement Disorders Center, McKnight Brain Institute, Department of Neurology, Gainesville, FL 32611, USA
Parkinsonism Relat Disord 16:517-21. 2010..To pilot a data-driven quality care program in National Parkinson Foundation (NPF) Centers of Excellence... - Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson diseaseRoy N Alcalay
Department of Neurology, Columbia University, New York, NY 10032, USA
Arch Neurol 66:1517-22. 2009.... - Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survivalSusan Gregory
Penn Neurological Institute, 330 South 9th Street, Philadelphia, PA 19107, USA
Neurology 58:485-7. 2002..Gastrostomy tubes were successfully placed in all patients. Mean survival was 211 days with most patients (67%) surviving more than 180 days. Forced vital capacity at the time of PEG placement did not predict survival... - Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapyN Dahodwala
Department of Neurology, Pennsylvania Hospital, University of Pennsylvania, USA
Parkinsonism Relat Disord 13:495-9. 2007..001). Interest in predictive testing for PD is moderate in the absence of effective therapy, and goes up significantly when both clinical trial participation and neuroprotective therapy are offered... - Multiple pathologies in a patient with a progressive neurodegenerative syndromeT W Liang
Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
J Neurol Neurosurg Psychiatry 76:252-5. 2005..This case raises the possibility that three distinct neuropathological diagnoses share a common aetiology... - Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030E R Dorsey
Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
Neurology 68:384-6. 2007..The number of individuals with PD over age 50 in these countries was between 4.1 and 4.6 million in 2005 and will double to between 8.7 and 9.3 million by 2030... - Development of quality of care indicators for Parkinson's diseaseEric M Cheng
Parkinson s Disease Research, Education Clinical Center PADRECC, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90073, USA
Mov Disord 19:136-50. 2004..01). An expert panel can reach consensus on a set of highly rated quality indicators for PD care, which can be used to assess quality of PD care and guide the design of quality improvement projects... - Serum urate as a predictor of clinical and radiographic progression in Parkinson diseaseMichael A Schwarzschild
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
Arch Neurol 65:716-23. 2008..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD... - Progressive supranuclear palsy: Setting the scene for therapeutic trialsAndrew Siderowf
Neurology 60:892-3. 2003 - Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudyPatrick D Mauldin
Department of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina, and the Ralph H Johnson VA Medical Center, Charleston, South Carolina 29425, USA
Clin Ther 30:1553-7. 2008....